Biography
Dr Vladimir Andelkovic is a Queensland-trained medical oncologist at Icon Cancer Centre South Brisbane and Icon Cancer Centre Wesley with clinical focus on complex malignancies requiring multidisciplinary care. He specializes in the treatment of bone and soft tissue sarcomas, gastrointestinal stromal tumours (GIST), and hepatobiliary cancers, including hepatocellular carcinoma.
As a member of the Sarcoma Multidisciplinary Teams at both Princess Alexandra and The Wesley Hospitals, Dr Andelkovic is deeply integrated into specialized clinical networks. He is a member of the Australia and New Zealand Sarcoma Association and the Connective Tissue Oncology Society, and he serves as a Principal Investigator on several clinical trials.
Dr Andelkovic is heavily involved in Phase I research at Icon South Brisbane, focusing on the development of emerging cancer therapies. His commitment to advancing the field extends to medical education, serving as a Senior Lecturer at the University of Queensland.
Publications
Giani, C., Baldi, G. G., Ljevar, S., Denu, R. A., Andelkovic, V., Han, I., Brunello, A., Napolitano, A., Bhadri, V. A., Scanferla, R., Garcia, A. S., Abreu, M. H., Campos, F., Ogura, K., Wong, D. D., Bae, S., Marquina, G., Mazzocca, A., Yang, V., … Stacchiotti, S. (2026). International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P RMS), a PUSH platform study: Outcome of primary localized disease. ESMO Open, 11(2), 106044. https://doi.org/10.1016/j.esmoop.2025.106044
Thavaneswaran, S., Lin, F., Espinoza, D., Grady, J., Kok, P. S., Chinchen, S., Pavlakis, N., Andelkovic, V., Charakidis, M., Craft, P., Brown, M., Desai, J., Lau, P., Kansara, M., Simes, J., & Thomas, D. (2025). A signal seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden. NPJ Precision Oncology, 9, 372. https://doi.org/10.1038/s41698-025-01156-5
Sklavos, T. J., Lawrence, S., Andelkovic, V., Cole, C., & Chacko, Y. (2025). Heart team rescues a bleeding heart: A case report of cardiac angiosarcoma causing life threatening tamponade. European Heart Journal Case Reports, 9(5), ytaf220. https://doi.org/10.1093/ehjcr/ytaf220
Giani, C., Denu, R. A., Ljevar, S., Gronchi, A., Napolitano, A., Rosenbaum, E., Salawu, A., Bajpai, J., Connolly, E. A., Lee, A. T. J., Trent, J. C., Koseła Paterczyk, H., Li, C., Ogura, K., Palmerini, E., Baldi, G. G., Brunello, A., Campos, F., Cicala, C. M., … Stacchiotti, S. (2024). Low grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma: Outcome of advanced disease. ESMO Open, 9(9), 103689. https://doi.org/10.1016/j.esmoop.2024.103689
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B. Y., Ren, Z., Masi, G., Kwiatkowski, M., Lim, H. Y., Kim, J. H., Breder, V., Kumada, H., Cheng, A. L., Galle, P. R., Kaneko, S., … Finn, R. S. (2023). Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP 002): A randomised, double blind, phase 3 trial. Lancet Oncology, 24(12), 1399–1410. https://doi.org/10.1016/S1470-2045(23)00469-2